Peptide Atlas · Peptide

Semaglutide

Semaglutide is a glucagon-like peptide-1 analogue with two amino acid substitutions (Aib8, Arg34) and a fatty-acid derivatization at lysine 26, designed for high albumin affinity and once-weekly dosing.

established

provisional
PubChem 56843331
3 citations
0 discussions
0 followers

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- established
  Claim: SUSTAIN-6 cardiovascular outcomes trial standing
- resolved
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators
pmid 27633186
- established
  Claim: STEP 1 trial in adults with overweight or obesity standing
- resolved
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group
pmid 33567185
- preclinical
  Claim: Discovery of the once-weekly GLP-1 analogue semaglutide standing
- resolved
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T
pmid 26308095

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.